Del Mar, CA, United States of America

Michael R Jackson

This inventor holds 25 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 3 EPO patents, primarily in Cell Therapy Research. Top assignees: Scripps Research Institute, Ortho-Mcneil Pharmaceutical Corp., Janssen Pharmaceuticals, Inc.. Active years: 1994-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael R Jackson. Retrieved from https://idiyas.com/inventor/michael-r-jackson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 

% Patents Active = 48.0

 

 

Average Co-Inventor Count = 4.8

ph-index = 10

Forward Citations = 227(Granted Patents)


Company Filing History:


Years Active: 1994-2015

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Cell Therapy
Cytotoxic T Lymphocytes
Antigen Presenting
T Cell Activation
Autoimmune Disease
Allergic Disease
MHC Class II
Synthetic Antigens
In Vitro Activation
Drosophila Cell Lines
Tumor Treatment
IgE Peptides
25 patents (USPTO):Explore Patents

Title: Michael R Jackson: A Pioneer in Cell Therapy Innovation

Introduction:

Michael R Jackson, a renowned inventor hailing from Del Mar, CA, has made significant contributions in the field of cell therapy for the treatment of tumors. With an impressive portfolio of 18 patents and a keen focus on developing innovative solutions, Jackson has emerged as a leading figure in the medical research community.

Innovations in Cell Therapy:

One of Jackson's notable inventions is a revolutionary cell therapy method for the treatment of tumors. This groundbreaking technique involves isolating, stimulating, and expanding naïve cytotoxic T lymphocyte precursors (CTLp) to antigen-specific effectors capable of targeting and destroying tumor cells in vivo.

To initiate a potent immune response, Jackson's method utilizes artificial antigen-presenting cells (AAPCs) transfected with human HLA class I molecules and specific accessory molecules. These artificial cells stimulate CD8T cells, both from cancer patients and normal donors, resulting in robust and reproducible polyclonal responses that specifically recognize and eliminate tumor cells expressing the targeted peptides.

The potency and adaptability of this artificial antigen expression system offer tremendous potential for treating a wide range of cancers in a significant majority of the population. Jackson's method stands out as a game-changer in the field of cancer immunotherapy, offering new hope for patients with compromised immune systems.

Companies and Collaborations:

Throughout his career, Michael R Jackson has collaborated with esteemed organizations such as The Scripps Research Institute and Ortho-McNeil Pharmaceutical Corp. These collaborations have provided the ideal platforms for developing and implementing his cutting-edge cell therapy innovations.

At The Scripps Research Institute, Jackson worked alongside notable colleagues such as Per A Peterson and Zeling Cai. Their collective expertise and dedication to pushing the boundaries of cell therapy research have resulted in groundbreaking advancements with vast potential for improving cancer treatment strategies.

Conclusion:

Michael R Jackson's accomplishments in cell therapy innovation highlight his commitment to revolutionizing cancer treatment. With 18 patents to his name, including his pioneering cell therapy method, Jackson has played a pivotal role in advancing cancer immunotherapy.

His contributions open up new possibilities for patients with compromised immune systems, offering hope for more effective, targeted, and personalized treatments. Michael R Jackson's relentless pursuit of innovative solutions epitomizes the spirit of inventiveness and dedication to transformative healthcare that drives the field of medical research forward.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…